鳥居薬品の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2023/03/10 | 3,215 | 3,330 | 3,215 | 3,290 | +15 | +0.5% | 43,100 |
2023/03/09 | 3,260 | 3,295 | 3,245 | 3,275 | +40 | +1.2% | 23,200 |
2023/03/08 | 3,210 | 3,255 | 3,190 | 3,235 | +25 | +0.8% | 17,900 |
2023/03/07 | 3,250 | 3,280 | 3,195 | 3,210 | -25 | -0.8% | 25,500 |
2023/03/06 | 3,225 | 3,285 | 3,200 | 3,235 | +50 | +1.6% | 43,400 |
2023/03/03 | 3,135 | 3,195 | 3,135 | 3,185 | +40 | +1.3% | 22,800 |
2023/03/02 | 3,140 | 3,155 | 3,130 | 3,145 | +40 | +1.3% | 11,700 |
2023/03/01 | 3,105 | 3,140 | 3,100 | 3,105 | -35 | -1.1% | 21,100 |
2023/02/28 | 3,105 | 3,155 | 3,090 | 3,140 | +15 | +0.5% | 60,100 |
2023/02/27 | 3,120 | 3,140 | 3,100 | 3,125 | -20 | -0.6% | 10,200 |
2023/02/24 | 3,185 | 3,185 | 3,130 | 3,145 | -55 | -1.7% | 29,700 |
2023/02/22 | 3,265 | 3,265 | 3,180 | 3,200 | -65 | -2% | 24,300 |
2023/02/21 | 3,275 | 3,285 | 3,255 | 3,265 | +10 | +0.3% | 12,400 |
2023/02/20 | 3,230 | 3,265 | 3,230 | 3,255 | +25 | +0.8% | 17,800 |
2023/02/17 | 3,235 | 3,240 | 3,205 | 3,230 | -10 | -0.3% | 15,200 |
2023/02/16 | 3,225 | 3,245 | 3,210 | 3,240 | +30 | +0.9% | 19,000 |
2023/02/15 | 3,210 | 3,225 | 3,185 | 3,210 | ±0 | ±0% | 29,500 |
2023/02/14 | 3,190 | 3,215 | 3,140 | 3,210 | +45 | +1.4% | 29,400 |
2023/02/13 | 3,160 | 3,185 | 3,095 | 3,165 | +5 | +0.2% | 48,300 |
2023/02/10 | 3,205 | 3,210 | 3,160 | 3,160 | -50 | -1.6% | 22,100 |
2023/02/09 | 3,175 | 3,225 | 3,175 | 3,210 | +35 | +1.1% | 19,400 |
2023/02/08 | 3,140 | 3,185 | 3,135 | 3,175 | +25 | +0.8% | 27,300 |
2023/02/07 | 3,150 | 3,185 | 3,135 | 3,150 | +20 | +0.6% | 36,100 |
2023/02/06 | 3,090 | 3,140 | 3,065 | 3,130 | +30 | +1% | 29,800 |
2023/02/03 | 3,080 | 3,120 | 3,065 | 3,100 | -20 | -0.6% | 35,900 |
2023/02/02 | 3,100 | 3,135 | 3,050 | 3,120 | +60 | +2% | 34,600 |
2023/02/01 | 3,105 | 3,105 | 3,035 | 3,060 | -45 | -1.4% | 23,900 |
2023/01/31 | 3,055 | 3,125 | 3,055 | 3,105 | +65 | +2.1% | 30,500 |
2023/01/30 | 3,005 | 3,050 | 2,990 | 3,040 | +35 | +1.2% | 20,300 |
2023/01/27 | 3,055 | 3,070 | 3,005 | 3,005 | -45 | -1.5% | 20,900 |
2023/01/26 | 3,090 | 3,090 | 3,035 | 3,050 | -30 | -1% | 14,800 |
2023/01/25 | 3,080 | 3,095 | 3,035 | 3,080 | ±0 | ±0% | 22,400 |
2023/01/24 | 3,190 | 3,215 | 3,065 | 3,080 | -110 | -3.4% | 65,400 |
2023/01/23 | 3,015 | 3,210 | 3,015 | 3,190 | +213 | +7.2% | 166,900 |
2023/01/20 | 2,947 | 2,999 | 2,947 | 2,977 | +30 | +1% | 28,200 |
2023/01/19 | 2,960 | 2,960 | 2,935 | 2,947 | -4 | -0.1% | 17,900 |
2023/01/18 | 2,924 | 2,965 | 2,924 | 2,951 | +35 | +1.2% | 29,300 |
2023/01/17 | 2,903 | 2,926 | 2,895 | 2,916 | +7 | +0.2% | 35,100 |
2023/01/16 | 2,866 | 2,937 | 2,866 | 2,909 | +18 | +0.6% | 13,600 |
2023/01/13 | 2,896 | 2,908 | 2,880 | 2,891 | -6 | -0.2% | 20,600 |
2023/01/12 | 2,892 | 2,915 | 2,883 | 2,897 | +18 | +0.6% | 12,600 |
2023/01/11 | 2,878 | 2,895 | 2,876 | 2,879 | +14 | +0.5% | 17,700 |
2023/01/10 | 2,855 | 2,874 | 2,845 | 2,865 | +13 | +0.5% | 18,000 |
2023/01/06 | 2,835 | 2,859 | 2,813 | 2,852 | +2 | +0.1% | 34,600 |
2023/01/05 | 2,900 | 2,950 | 2,834 | 2,850 | -48 | -1.7% | 33,100 |
2023/01/04 | 2,900 | 2,913 | 2,874 | 2,898 | -16 | -0.5% | 37,200 |
2022/12/30 | 2,913 | 2,965 | 2,912 | 2,914 | -3 | -0.1% | 29,000 |
2022/12/29 | 2,841 | 2,920 | 2,839 | 2,917 | +52 | +1.8% | 37,300 |
2022/12/28 | 2,858 | 2,885 | 2,849 | 2,865 | -4 | -0.1% | 42,800 |
2022/12/27 | 2,881 | 2,888 | 2,867 | 2,869 | +10 | +0.3% | 11,500 |
301~
350
件表示中 / 3467件
類似銘柄と比較する
現在ご覧いただいている「鳥居薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
鳥居薬 | 378,500円 | +7.3% | +16.8% | 3.17% | 22.64倍 | 0.89倍 |
|
JT傘下。自社製品の腎・透析、アレルゲン等の開発強化。柱の抗HIV薬の販売権喪失が直撃 |
杏林製薬 | 171,500円 | +3.2% | +4.5% | 3.03% | 19.71倍 | 0.75倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
ジーエヌアイ | 220,300円 | +52.1% | +23.3% | 0.00% | 15.60倍 | 3.26倍 |
|
創薬ベンチャー。米国で人工骨も。中国の特発性肺線維症薬で高シェア、米中に研究開発機能 |
ゼリア新薬 | 198,700円 | +9.6% | +17.5% | 2.32% | 11.23倍 | 1.10倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
栄研化 | 209,700円 | +7.6% | +57.5% | 2.53% | 16.19倍 | 1.59倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割弱。尿検査(ウロ)、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム